BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 27681240)

  • 1. (1S,2E,4S,7E,11E)-2,7,11-Cembratriene-4,6-diol semisynthetic analogs as novel c-Met inhibitors for the control of c-Met-dependent breast malignancies.
    Ebrahim HY; Mohyeldin MM; Hailat MM; El Sayed KA
    Bioorg Med Chem; 2016 Nov; 24(22):5748-5761. PubMed ID: 27681240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The tobacco cembranoid (1S,2E,4S,7E,11E)-2,7,11-cembratriene-4,6-diol as a novel angiogenesis inhibitory lead for the control of breast malignancies.
    Hailat MM; Ebrahim HY; Mohyeldin MM; Goda AA; Siddique AB; El Sayed KA
    Bioorg Med Chem; 2017 Aug; 25(15):3911-3921. PubMed ID: 28583806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biocatalytic and semisynthetic optimization of the anti-invasive tobacco (1S,2E,4R,6R,7E,11E)-2,7,11-cembratriene-4,6-diol.
    El Sayed KA; Laphookhieo S; Baraka HN; Yousaf M; Hebert A; Bagaley D; Rainey FA; Muralidharan A; Thomas S; Shah GV
    Bioorg Med Chem; 2008 Mar; 16(6):2886-93. PubMed ID: 18222089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The indole alkaloid meleagrin, from the olive tree endophytic fungus Penicillium chrysogenum, as a novel lead for the control of c-Met-dependent breast cancer proliferation, migration and invasion.
    Mady MS; Mohyeldin MM; Ebrahim HY; Elsayed HE; Houssen WE; Haggag EG; Soliman RF; El Sayed KA
    Bioorg Med Chem; 2016 Jan; 24(2):113-22. PubMed ID: 26692349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationally designed hecogenin thiosemicarbazone analogs as novel MEK inhibitors for the control of breast malignancies.
    Elsayed HE; Ebrahim HY; Haggag EG; Kamal AM; El Sayed KA
    Bioorg Med Chem; 2017 Dec; 25(24):6297-6312. PubMed ID: 29066046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The oleocanthal-based homovanillyl sinapate as a novel c-Met inhibitor.
    Mohyeldin MM; Akl MR; Ebrahim HY; Dragoi AM; Dykes S; Cardelli JA; El Sayed KA
    Oncotarget; 2016 May; 7(22):32247-73. PubMed ID: 27086914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and antitumor evaluation of novel 5-methylpyrazolo[1,5-a]pyrimidine derivatives as potential c-Met inhibitors.
    Luo G; Ma Y; Liang X; Xie G; Luo Y; Zha D; Wang S; Yu L; Zheng X; Wu W; Zhang C
    Bioorg Chem; 2020 Nov; 104():104356. PubMed ID: 33142417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-based discovery of novel 4-(2-fluorophenoxy)quinoline derivatives as c-Met inhibitors using isocyanide-involved multicomponent reactions.
    Nan X; Li HJ; Fang SB; Li QY; Wu YC
    Eur J Med Chem; 2020 May; 193():112241. PubMed ID: 32200199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Norstictic Acid Inhibits Breast Cancer Cell Proliferation, Migration, Invasion, and In Vivo Invasive Growth Through Targeting C-Met.
    Ebrahim HY; Elsayed HE; Mohyeldin MM; Akl MR; Bhattacharjee J; Egbert S; El Sayed KA
    Phytother Res; 2016 Apr; 30(4):557-66. PubMed ID: 26744260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Semisynthetic and biotransformation studies of (1S,2E,4S,6R,7E,11E)-2,7,11-cembratriene-4,6-diol.
    El Sayed KA; Laphookhieo S; Yousaf M; Prestridge JA; Shirode AB; Wali VB; Sylvester PW
    J Nat Prod; 2008 Jan; 71(1):117-22. PubMed ID: 18177013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological evaluation of novel 4-phenoxy-6,7-disubstituted quinolines possessing (thio)semicarbazones as c-Met kinase inhibitors.
    Zhai X; Bao G; Wang L; Cheng M; Zhao M; Zhao S; Zhou H; Gong P
    Bioorg Med Chem; 2016 Mar; 24(6):1331-45. PubMed ID: 26897090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rutin as A Novel c-Met Inhibitory Lead for The Control of Triple Negative Breast Malignancies.
    Elsayed HE; Ebrahim HY; Mohyeldin MM; Siddique AB; Kamal AM; Haggag EG; El Sayed KA
    Nutr Cancer; 2017; 69(8):1256-1271. PubMed ID: 29083228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and biological evaluation of novel N-sulfonylamidine-based derivatives as c-Met inhibitors via Cu-catalyzed three-component reaction.
    Nan X; Zhang J; Li HJ; Wu R; Fang SB; Zhang ZZ; Wu YC
    Eur J Med Chem; 2020 Aug; 200():112470. PubMed ID: 32505087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Target identification, lead optimization and antitumor evaluation of some new 1,2,4-triazines as c-Met kinase inhibitors.
    El-Wakil MH; Ashour HM; Saudi MN; Hassan AM; Labouta IM
    Bioorg Chem; 2017 Aug; 73():154-169. PubMed ID: 28715754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and biological evaluation of novel 4-phenoxypyridine based 3-oxo-3,4-dihydroquinoxaline-2-carboxamide derivatives as potential c-Met kinase inhibitors.
    Wang Z; Shi J; Zhu X; Zhao W; Gong Y; Hao X; Hou Y; Liu Y; Ding S; Liu J; Chen Y
    Bioorg Chem; 2020 Dec; 105():104371. PubMed ID: 33075664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of novel pyrrolo-pyridine/pyrimidine derivatives bearing pyridazinone moiety as c-Met kinase inhibitors.
    Wang LX; Liu X; Xu S; Tang Q; Duan Y; Xiao Z; Zhi J; Jiang L; Zheng P; Zhu W
    Eur J Med Chem; 2017 Dec; 141():538-551. PubMed ID: 29107421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis of novel 6,7-dimethoxy-4-anilinoquinolines as potent c-Met inhibitors.
    Zhang QW; Ye ZD; Shen C; Tie HX; Wang L; Shi L
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):124-133. PubMed ID: 30422010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of 3,6-disubstituted pyridazines as a novel class of anticancer agents targeting cyclin-dependent kinase 2: synthesis, biological evaluation and in silico insights.
    Sabt A; Eldehna WM; Al-Warhi T; Alotaibi OJ; Elaasser MM; Suliman H; Abdel-Aziz HA
    J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1616-1630. PubMed ID: 32781872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, Synthesis and Biological Evaluation of Novel 4-phenoxypyridine Derivatives Containing Semicarbazones Moiety as Potential c-Met Kinase Inhibitors.
    Li J; Li J; Zhang J; Shi J; Ding S; Liu Y; Chen Y; Liu J
    Anticancer Agents Med Chem; 2020; 20(5):559-570. PubMed ID: 31893997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective activity of (1S,2E,4R,6R,7E,11E)-2,7,11-cembratriene-4,6-diol analogues against diisopropylfluorophosphate neurotoxicity: preliminary structure-activity relationship and pharmacophore modeling.
    Eterović VA; Del Valle-Rodriguez A; Pérez D; Carrasco M; Khanfar MA; El Sayed KA; Ferchmin PA
    Bioorg Med Chem; 2013 Aug; 21(15):4678-86. PubMed ID: 23769165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.